Kirsten Cremer
University of Bonn
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kirsten Cremer.
The Lancet | 2012
Anita Rauch; Dagmar Wieczorek; Elisabeth Graf; Thomas Wieland; Sabine Endele; Thomas Schwarzmayr; Beate Albrecht; Deborah Bartholdi; Jasmin Beygo; Nataliya Di Donato; Andreas Dufke; Kirsten Cremer; Maja Hempel; Denise Horn; Juliane Hoyer; Pascal Joset; Albrecht Röpke; Ute Moog; Angelika Riess; Christian Thiel; Andreas Tzschach; Antje Wiesener; Eva Wohlleber; Christiane Zweier; Arif B. Ekici; Alexander M. Zink; Andreas Rump; Christa Meisinger; Harald Grallert; Heinrich Sticht
BACKGROUND The genetic cause of intellectual disability in most patients is unclear because of the absence of morphological clues, information about the position of such genes, and suitable screening methods. Our aim was to identify de-novo variants in individuals with sporadic non-syndromic intellectual disability. METHODS In this study, we enrolled children with intellectual disability and their parents from ten centres in Germany and Switzerland. We compared exome sequences between patients and their parents to identify de-novo variants. 20 children and their parents from the KORA Augsburg Diabetes Family Study were investigated as controls. FINDINGS We enrolled 51 participants from the German Mental Retardation Network. 45 (88%) participants in the case group and 14 (70%) in the control group had de-novo variants. We identified 87 de-novo variants in the case group, with an exomic mutation rate of 1·71 per individual per generation. In the control group we identified 24 de-novo variants, which is 1·2 events per individual per generation. More participants in the case group had loss-of-function variants than in the control group (20/51 vs 2/20; p=0·022), suggesting their contribution to disease development. 16 patients carried de-novo variants in known intellectual disability genes with three recurrently mutated genes (STXBP1, SYNGAP1, and SCN2A). We deemed at least six loss-of-function mutations in six novel genes to be disease causing. We also identified several missense alterations with potential pathogenicity. INTERPRETATION After exclusion of copy-number variants, de-novo point mutations and small indels are associated with severe, sporadic non-syndromic intellectual disability, accounting for 45-55% of patients with high locus heterogeneity. Autosomal recessive inheritance seems to contribute little in the outbred population investigated. The large number of de-novo variants in known intellectual disability genes is only partially attributable to known non-specific phenotypes. Several patients did not meet the expected syndromic manifestation, suggesting a strong bias in present clinical syndrome descriptions. FUNDING German Ministry of Education and Research, European Commission 7th Framework Program, and Swiss National Science Foundation.
American Journal of Human Genetics | 2012
Lia Abbasi-Moheb; Sara Mertel; Melanie Gonsior; Leyla Nouri-Vahid; Kimia Kahrizi; Sebahattin Cirak; Dagmar Wieczorek; M. Mahdi Motazacker; Sahar Esmaeeli-Nieh; Kirsten Cremer; Robert Weißmann; Andreas Tzschach; Masoud Garshasbi; Seyedeh Sedigheh Abedini; Hossein Najmabadi; Hans-Hilger Ropers; Stephan J. Sigrist; Andreas W. Kuss
With a prevalence between 1 and 3%, hereditary forms of intellectual disability (ID) are among the most important problems in health care. Particularly, autosomal-recessive forms of the disorder have a very heterogeneous molecular basis, and genes with an increased number of disease-causing mutations are not common. Here, we report on three different mutations (two nonsense mutations, c.679C>T [p.Gln227(∗)] and c.1114C>T [p.Gln372(∗)], as well as one splicing mutation, g.6622224A>C [p.Ile179Argfs(∗)192]) that cause a loss of the tRNA-methyltransferase-encoding NSUN2 main transcript in homozygotes. We identified the mutations by sequencing exons and exon-intron boundaries within the genomic region where the linkage intervals of three independent consanguineous families of Iranian and Kurdish origin overlapped with the previously described MRT5 locus. In order to gain further evidence concerning the effect of a loss of NSUN2 on memory and learning, we constructed a Drosophila model by deleting the NSUN2 ortholog, CG6133, and investigated the mutants by using molecular and behavioral approaches. When the Drosophila melanogaster NSUN2 ortholog was deleted, severe short-term-memory (STM) deficits were observed; STM could be rescued by re-expression of the wild-type protein in the nervous system. The humans homozygous for NSUN2 mutations showed an overlapping phenotype consisting of moderate to severe ID and facial dysmorphism (which includes a long face, characteristic eyebrows, a long nose, and a small chin), suggesting that mutations in this gene might even induce a syndromic form of ID. Moreover, our observations from the Drosophila model point toward an evolutionarily conserved role of RNA methylation in normal cognitive development.
Molecular Syndromology | 2012
Marjolein H. Willemsen; A.T. Vulto-van Silfhout; Willy M. Nillesen; Willemijn Wissink-Lindhout; H. van Bokhoven; N. Philip; Elizabeth Berry-Kravis; Usha Kini; C.M.A. van Ravenswaaij-Arts; B. Delle Chiaie; A.M.M. Innes; Gunnar Houge; T. Kosonen; Kirsten Cremer; Madeleine Fannemel; Asbjørg Stray-Pedersen; Willie Reardon; J. Ignatius; Katherine Lachlan; C. Mircher; P.T.J.M. Helderman van den Enden; M. Mastebroek; P.E. Cohn-Hokke; Helger G. Yntema; S. Drunat; Tjitske Kleefstra
Kleefstra syndrome is characterized by the core phenotype of developmental delay/intellectual disability, (childhood) hypotonia and distinct facial features. The syndrome can be either caused by a microdeletion in chromosomal region 9q34.3 or by a mutation in the euchromatin histone methyltransferase 1 (EHMT1) gene. Since the early 1990s, 85 patients have been described, of which the majority had a 9q34.3 microdeletion (>85%). So far, no clear genotype-phenotype correlation could be observed by studying the clinical and molecular features of both 9q34.3 microdeletion patients and patients with an intragenic EHMT1 mutation. Thus, to further expand the genotypic and phenotypic knowledge about the syndrome, we here report 29 newly diagnosed patients, including 16 patients with a 9q34.3 microdeletion and 13 patients with an EHMT1 mutation, and review previous literature. The present findings are comparable to previous reports. In addition to our former findings and recommendations, we suggest cardiac screening during follow-up, because of the possible occurrence of cardiac arrhythmias. In addition, clinicians and caretakers should be aware of the regressive behavioral phenotype that might develop at adolescent/adult age and seems to have no clear neurological substrate, but is rather a so far unexplained neuropsychiatric feature.
European Journal of Human Genetics | 2011
Ute Grasshoff; Michael Bonin; Ina Goehring; Arif B. Ekici; Andreas Dufke; Kirsten Cremer; Nicholas Wagner; Eva Rossier; Anna Jauch; Michael A. Walter; Claudia Bauer; Peter Bauer; Karl Horber; Stefanie Beck-Woedl; Dagmar Wieczorek
Xq28 duplications including MECP2 are a well-known cause of severe mental retardation in males with seizures, muscular hypotonia, progressive spasticity, poor speech and recurrent infections that often lead to early death. Female carriers usually show a normal intellectual performance due to skewed X-inactivation (XCI). We report on two female patients with a de novo MECP2 duplication associated with moderate mental retardation. In both patients, the de novo duplication occurred on the paternal allele, and both patients show a random XCI, which can be assumed as the triggering factor for the phenotype. Furthermore, we describe the phenotype that might be restricted to unspecific mild-to -moderate mental retardation with neurological features in early adulthood.
Annals of clinical and translational neurology | 2015
Tobias B. Haack; Christopher B. Jackson; Kei Murayama; Laura S. Kremer; André Schaller; Urania Kotzaeridou; Maaike C. de Vries; Gudrun Schottmann; Saikat Santra; Boriana Büchner; Thomas Wieland; Elisabeth Graf; Peter Freisinger; Seila Eggimann; Akira Ohtake; Yasushi Okazaki; Masakazu Kohda; Yoshihito Kishita; Yoshimi Tokuzawa; Sascha Sauer; Yasin Memari; Anja Kolb-Kokocinski; Richard Durbin; Oswald Hasselmann; Kirsten Cremer; Beate Albrecht; Dagmar Wieczorek; Hartmut Engels; Dagmar Hahn; Alexander M. Zink
Short‐chain enoyl‐CoA hydratase (ECHS1) is a multifunctional mitochondrial matrix enzyme that is involved in the oxidation of fatty acids and essential amino acids such as valine. Here, we describe the broad phenotypic spectrum and pathobiochemistry of individuals with autosomal‐recessive ECHS1 deficiency.
Human Genetics | 2015
Alma Kuechler; Marjolein H. Willemsen; Beate Albrecht; Carlos A. Bacino; Dennis Bartholomew; Hans van Bokhoven; Marie Jose H. van den Boogaard; Nuria C. Bramswig; Christian Büttner; Kirsten Cremer; Johanna Christina Czeschik; Hartmut Engels; Koen L.I. van Gassen; Elisabeth Graf; Mieke M. van Haelst; Weimin He; Jacob Hogue; Marlies Kempers; David A. Koolen; Glen R. Monroe; Sonja de Munnik; Matthew Pastore; André Reis; Miriam S. Reuter; David Tegay; Joris A. Veltman; Gepke Visser; Peter M. van Hasselt; Eric Smeets; Lisenka E.L.M. Vissers
Recently, de novo heterozygous loss-of-function mutations in beta-catenin (CTNNB1) were described for the first time in four individuals with intellectual disability (ID), microcephaly, limited speech and (progressive) spasticity, and functional consequences of CTNNB1 deficiency were characterized in a mouse model. Beta-catenin is a key downstream component of the canonical Wnt signaling pathway. Somatic gain-of-function mutations have already been found in various tumor types, whereas germline loss-of-function mutations in animal models have been shown to influence neuronal development and maturation. We report on 16 additional individuals from 15 families in whom we newly identified de novo loss-of-function CTNNB1 mutations (six nonsense, five frameshift, one missense, two splice mutation, and one whole gene deletion). All patients have ID, motor delay and speech impairment (both mostly severe) and abnormal muscle tone (truncal hypotonia and distal hypertonia/spasticity). The craniofacial phenotype comprised microcephaly (typically −2 to −4 SD) in 12 of 16 and some overlapping facial features in all individuals (broad nasal tip, small alae nasi, long and/or flat philtrum, thin upper lip vermillion). With this detailed phenotypic characterization of 16 additional individuals, we expand and further establish the clinical and mutational spectrum of inactivating CTNNB1 mutations and thereby clinically delineate this new CTNNB1 haploinsufficiency syndrome.
European Journal of Human Genetics | 2014
Alma Kuechler; Alexander M. Zink; Thomas Wieland; Hermann-Josef Lüdecke; Kirsten Cremer; Leonardo Salviati; Pamela Magini; Kimia Najafi; Christiane Zweier; Johanna Christina Czeschik; Stefan Aretz; Sabine Endele; Federica Tamburrino; Claudia Pinato; Maurizio Clementi; Jasmin Gundlach; Carina Maylahn; Laura Mazzanti; Eva Wohlleber; Thomas Schwarzmayr; Roxana Kariminejad; Avner Schlessinger; Dagmar Wieczorek; Tim M. Strom; Gaia Novarino; Hartmut Engels
Intellectual disability (ID) has an estimated prevalence of 2–3%. Due to its extreme heterogeneity, the genetic basis of ID remains elusive in many cases. Recently, whole exome sequencing (WES) studies revealed that a large proportion of sporadic cases are caused by de novo gene variants. To identify further genes involved in ID, we performed WES in 250 patients with unexplained ID and their unaffected parents and included exomes of 51 previously sequenced child–parents trios in the analysis. Exome analysis revealed de novo intragenic variants in SET domain-containing 5 (SETD5) in two patients. One patient carried a nonsense variant, and the other an 81 bp deletion located across a splice-donor site. Chromosomal microarray diagnostics further identified four de novo non-recurrent microdeletions encompassing SETD5. CRISPR/Cas9 mutation modelling of the two intragenic variants demonstrated nonsense-mediated decay of the resulting transcripts, pointing to a loss-of-function (LoF) and haploinsufficiency as the common disease-causing mechanism of intragenic SETD5 sequence variants and SETD5-containing microdeletions. In silico domain prediction of SETD5, a predicted SET domain-containing histone methyltransferase (HMT), substantiated the presence of a SET domain and identified a novel putative PHD domain, strengthening a functional link to well-known histone-modifying ID genes. All six patients presented with ID and certain facial dysmorphisms, suggesting that SETD5 sequence variants contribute substantially to the microdeletion 3p25.3 phenotype. The present report of two SETD5 LoF variants in 301 patients demonstrates a prevalence of 0.7% and thus SETD5 variants as a relatively frequent cause of ID.
American Journal of Human Genetics | 2015
Maja Hempel; Kirsten Cremer; Charlotte W. Ockeloen; Klaske D. Lichtenbelt; Johanna C. Herkert; Jonas Denecke; Tobias B. Haack; Alexander M. Zink; Jessica Becker; Eva Wohlleber; Jessika Johannsen; Bader Alhaddad; Rolph Pfundt; Sigrid Fuchs; Dagmar Wieczorek; Tim M. Strom; Koen L.I. van Gassen; Tjitske Kleefstra; Christian Kubisch; Hartmut Engels; Davor Lessel
CHAMP1 encodes a protein with a function in kinetochore-microtubule attachment and in the regulation of chromosome segregation, both of which are known to be important for neurodevelopment. By trio whole-exome sequencing, we have identified de novo deleterious mutations in CHAMP1 in five unrelated individuals affected by intellectual disability with severe speech impairment, motor developmental delay, muscular hypotonia, and similar dysmorphic features including short philtrum and a tented upper and everted lover lip. In addition to two frameshift and one nonsense mutations, we found an identical nonsense mutation, c.1192C>T (p.Arg398*), in two affected individuals. All mutations, if resulting in a stable protein, are predicted to lead to the loss of the functionally important zinc-finger domains in the C terminus of the protein, which regulate CHAMP1 localization to chromosomes and the mitotic spindle, thereby providing a mechanistic understanding for their pathogenicity. We thus establish deleterious de novo mutations in CHAMP1 as a cause of intellectual disability.
American Journal of Human Genetics | 2017
Yair Anikster; Tobias B. Haack; Thierry Vilboux; Ben Pode-Shakked; Beat Thöny; Nan Shen; Virginia Guarani; Thomas Meissner; Ertan Mayatepek; Friedrich K. Trefz; Dina Marek-Yagel; Aurora Martinez; Edward L. Huttlin; Joao A. Paulo; Riccardo Berutti; Jean-François Benoist; Apolline Imbard; Imen Dorboz; Gali Heimer; Yuval E. Landau; Limor Ziv-Strasser; May Christine V. Malicdan; Corinne Gemperle-Britschgi; Kirsten Cremer; Hartmut Engels; David Meili; Irene Keller; Rémy Bruggmann; Tim M. Strom; Thomas Meitinger
Phenylketonuria (PKU, phenylalanine hydroxylase deficiency), an inborn error of metabolism, can be detected through newborn screening for hyperphenylalaninemia (HPA). Most individuals with HPA harbor mutations in the gene encoding phenylalanine hydroxylase (PAH), and a small proportion (2%) exhibit tetrahydrobiopterin (BH4) deficiency with additional neurotransmitter (dopamine and serotonin) deficiency. Here we report six individuals from four unrelated families with HPA who exhibited progressive neurodevelopmental delay, dystonia, and a unique profile of neurotransmitter deficiencies without mutations in PAH or BH4 metabolism disorder-related genes. In these six affected individuals, whole-exome sequencing (WES) identified biallelic mutations in DNAJC12, which encodes a heat shock co-chaperone family member that interacts with phenylalanine, tyrosine, and tryptophan hydroxylases catalyzing the BH4-activated conversion of phenylalanine into tyrosine, tyrosine into L-dopa (the precursor of dopamine), and tryptophan into 5-hydroxytryptophan (the precursor of serotonin), respectively. DNAJC12 was undetectable in fibroblasts from the individuals with null mutations. PAH enzyme activity was reduced in the presence of DNAJC12 mutations. Early treatment with BH4 and/or neurotransmitter precursors had dramatic beneficial effects and resulted in the prevention of neurodevelopmental delay in the one individual treated before symptom onset. Thus, DNAJC12 deficiency is a preventable and treatable cause of intellectual disability that should be considered in the early differential diagnosis when screening results are positive for HPA. Sequencing of DNAJC12 may resolve any uncertainty and should be considered in all children with unresolved HPA.
European Journal of Medical Genetics | 2008
Kirsten Cremer; Hermann-Josef Lüdecke; Frauke Ruhr; Dagmar Wieczorek
Deletion of 1p36 (OMIM 607872) is estimated to be the most common distal terminal deletion syndrome. We describe a previously unreported, typically affected two-month-old girl with this microdeletion syndrome, who additionally suffers from left-ventricular non-compaction (LVNC). Recently, this congenital heart defect, characterized by prominent left-ventricular trabeculae and deep intertrabecular recesses, was reported in 12 further patients (excluding those reported only in abstract form) with terminal deletion of 1p36, leading to the conclusion that this cardiomyopathy is common in patients with this chromosomal aberration. We hypothesize that a gene in 1p36 might be responsible for LVNC.